Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-hodgkin’s lymphoma

[1]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. , 2004, Blood.

[2]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.

[3]  M. Pfreundschuh,et al.  Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. V. Von Roenn,et al.  Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[6]  N. Saijo,et al.  Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay , 2004, Cancer Chemotherapy and Pharmacology.

[7]  G. Schwarzer,et al.  Impact of granulocyte colony‐stimulating factor (CSF) and granulocyte–macrophage CSF in patients with malignant lymphoma: a systematic review , 2003, British journal of haematology.

[8]  R. Fisher,et al.  Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Wilson,et al.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. , 2003, Blood.

[10]  J. Vose,et al.  Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Piccart,et al.  A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Staudt,et al.  Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. , 2002, Blood.

[13]  L. R. Hill,et al.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[15]  E. Korn,et al.  A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. , 2001, Blood.

[16]  V. Jain,et al.  A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma. , 2001, Clinical lymphoma.

[17]  W. Wilson,et al.  Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Niedzwiecki,et al.  Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255 , 2000 .

[19]  M. Christian,et al.  Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Bloomfield,et al.  The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 , 2000, Modern Pathology.

[21]  G. Castoldi,et al.  Short term treatment with Escheria coli recombinant human granulocyte‐macrophage–colony stimulating factor prior to chemotherapy for Hodgkin disease , 2000, Cancer.

[22]  L. Gordon,et al.  A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. , 1999, Blood.

[23]  M. Somerfield,et al.  Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Cheang,et al.  Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Postmus,et al.  Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Maloney,et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Demidem,et al.  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.

[28]  R. Fisher.  Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma , 1997, Cancer Chemotherapy and Pharmacology.

[29]  J. Doroshow,et al.  Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion. , 1996, The Journal of infusional chemotherapy.

[30]  F. Arroyo,et al.  Infusional Chemotherapy (EPOCH) in Patients with Refractory or Relapsed Lymphoma , 1995, American Journal of Clinical Oncology.

[31]  W. Wilson,et al.  EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Sparano,et al.  Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Sparano,et al.  Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen , 1993 .

[34]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[35]  R. Frenck,et al.  Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Bates,et al.  P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines , 1991, International journal of cancer.

[37]  J. Shuster,et al.  The 2 x 2 matched-pairs trial: exact unconditional design and analysis. , 1991, Biometrics.

[38]  R A Olshen,et al.  Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Teicher,et al.  Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. , 1989, Cancer research.

[40]  W. Piacibello,et al.  Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. , 1989, The Journal of clinical investigation.

[41]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[42]  R. Fisher,et al.  Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. , 1981, Blood.

[43]  David P. Harrington,et al.  A class of hypothesis tests for one and two sample censored survival data , 1981 .

[44]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[46]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .